Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL365285 | 0.92 | SCN9A (0.52) | SCN3ASCN9ANR1H4SCN5AMRGPRX4 | |
| SCHEMBL14890492 | 0.86 | MAOA (0.52) | SCN3ASCN9ANR1H4SCN5AMRGPRX4 | |
| SCHEMBL364245 | 0.86 | MAOA (0.65) | SCN3ASCN9ASCN5AMAOAMAOB | |
| SCHEMBL365474 | 0.81 | MAOB (0.67) | MRGPRX4MAOAMAOBBCL2L1MCL1 | |
| SCHEMBL365210 | 0.80 | MAOA (0.63) | SCN9ASCN5AMAOAMAOBSMN1; SMN2 | |
| SCHEMBL366081 | 0.80 | MAOA (0.63) | SCN9ASCN5AMAOAMAOBSMN1; SMN2 | |
| SCHEMBL365173 | 0.80 | MAOB (0.61) | SCN3ANR1H4MAOBSMN1; SMN2BCL2L1 | |
| SCHEMBL10203178 | 0.80 | SCN9A (0.66) | SCN9ASCN5AMRGPRX4MAOAMAOB | |
| SCHEMBL10396460 | 0.79 | NR1H4 (0.62) | NR1H4MAOAMAOBSMN1; SMN2NR4A2 | |
| SCHEMBL367348 | 0.79 | BCL2L1 (0.57) | SCN3ASCN9ASCN5AMRGPRX4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN3A 7/4885SCN9A 16/4885NR1H4 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.